Cardurion
Changing the Course of Cardiovascular Disease.
- Headquarters
- Burlington, Massachusetts
- Employees
- 11–50
- Founded
- 2017
- Business Model
- B2B
- Website
- cardurion.com
- Total Funding
- $560.0M
- Last Round
- $260.0M Series BJul 2024
About
Cardurion Pharmaceuticals is a clinical-stage biotechnology company pioneering next-generation therapeutics for cardiovascular disease. The company has two active clinical programs: a PDE9 inhibitor (CRD-750) in Phase 2 trials for heart failure, and a CaMKII inhibitor for rare arrhythmias including catecholaminergic polymorphic ventricular tachycardia (CPVT) and broader cardiovascular indications. Founded by physician-scientist Dr. Michael E. Mendelsohn, Cardurion is backed by Bain Capital Life Sciences, headquartered in Burlington, Massachusetts with a research affiliate in Japan.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account